Workflow
Drug approval and sales growth
icon
Search documents
AbbVie Pins Hopes on Rinvoq to Drive Next Phase of Growth
ZACKS· 2025-08-22 14:41
Key Takeaways Rinvoq met primary and secondary endpoints in the second phase III alopecia areata study.ABBV plans to file for Rinvoq's alopecia areata approval in 2025, with more phase III data ahead.Rinvoq delivered $3.7B in H1 2025 sales, up 49% year over year, and is on track to reach $8.2B.AbbVie (ABBV) holds a dominant position in the immunology market, which is being aided by strong sales of its two new immunology medicines, Rinvoq and Skyrizi. The drugs have not only mitigated the impact of Humira’s ...